Indiana 2026 Regular Session

Indiana House Bill HB1114

Introduced
1/5/26  
Refer
1/5/26  
Report Pass
1/20/26  
Engrossed
1/29/26  
Refer
2/2/26  
Refer
2/12/26  
Report Pass
2/19/26  
Enrolled
2/24/26  
Passed
3/3/26  
Chaptered
3/3/26  

Caption

A BILL FOR AN ACT to amend the Indiana Code concerning insurance.

Impact

If enacted, HB 1114 will directly influence the insurance coverage protocols regarding cancer treatment within state employee health plans. The bill reinforces the importance of immediate access to effective medications for advanced cancer patients without imposing additional barriers related to prior drug failures. The change is expected to support better health outcomes by allowing timely access to necessary treatments based on peer-reviewed best practices rather than administrative hurdles.

Summary

House Bill 1114 aims to amend the Indiana Code concerning health insurance provisions for state employees. Specifically, it focuses on the coverage of prescription drugs for the treatment of advanced, metastatic cancer and associated conditions. The bill stipulates that state employee health plans will not require individuals to have previously failed treatments before obtaining coverage for these specific prescription drugs. This legislative effort is intended to enhance access to essential medications for employees affected by severe health conditions.

Sentiment

The general sentiment surrounding HB 1114 appears supportive, particularly among advocates for cancer patients and healthcare access. Proponents highlight the importance of ensuring that individuals dealing with severe health challenges are not forced to navigate complex prior authorization processes that could delay treatment. Further, the sentiment reflects a recognition of the necessity for policies that prioritize patient health over bureaucratic constraints.

Contention

There are potential points of contention related to the bill, particularly concerning the balance between insurance cost controls and providing necessary coverage. Opponents may raise concerns about the fiscal impact on state health plans if requirements for drug approval are relaxed. Although no significant opposition was noted in the documented discussions or voting records, as with any significant healthcare legislation, there could be financial implications that warrant careful consideration and analysis.

Companion Bills

No companion bills found.

Similar Bills

No similar bills found.